Skip to content

Research at St Andrews

Fixed dose darunavir boosted with cobicistat combined with emtricitabine and tenofovir alafenamide fumarate

Research output: Contribution to journalReview article


Muge Cevik, Chloe Orkin

School/Research organisations


Purpose of review: In an era when virological efficacy approaches 100%, novel antiretroviral (ARV) therapies must deliver better tolerability, safety, and convenient coformulated regimens. We review the phase II and III clinical data on the fixed dose combination (FDC) darunavir (DRV) 800mg / cobicistat (COBI/C) 150 mg / emtricitabine (F/FTC) 200 mg / tenofovir alafenamide fumarate (TAF) 10mg (D/C/F/TAF) for the treatment of HIV-1 infection.

Recent finding: In an exploratory phase II study, D/C/F/TAF FDC demonstrated similar virological efficacy to darunavir/cobicistat FDC + F /tenofovir disoproxil fumarate (TDF) FDC in treatment-naive HIV-1-infected individuals with favorable bone and renal outcomes. These findings led to two subsequent international phase III double-blind randomized controlled trials; AMBER and EMERALD. In the (treatment naïve) AMBER study, D/C/F/TAF FDC was noninferior to component regimen F/TDF + darunavir/cobicistat with favorable bone and renal outcomes at week 48. In the EMERALD study (switch study for virologically suppressed patients), D/C/F/TAF showed noninferior efficacy to F/TDF and boosted protease inhibitor (bPI) regimen at week 48 also with favorable renal and bone outcomes. No virological failure was observed, and no resistance to TDF or darunavir emerged in either study.

Summary: In clinical trials, D/C/F/TAF FDC demonstrated excellent, noninferior virological efficacy, maintained a high genetic barrier and conferred the additional safety benefits of TAF. As the first one pill, once daily, protease inhibitor-based regimen, D/C/F/TAF FDC offers a new option for the treatment of HIV infection.



Original languageEnglish
Pages (from-to)315-319
Number of pages5
JournalCurrent opinion in HIV and AIDS
Issue number4
Publication statusPublished - 1 Jul 2018

    Research areas

  • Anti-HIV Agents/administration & dosage, Clinical trials, Phase II as topic, Clinical trials, Phase III as topic, Darunavir/administration & dosage, Drug therapy, combination, Emtricitabine/administration & dosage, HIV Infections/drug therapy, Humans, Randomized controlled trials as topic, Tenofovir/administration & dosage

Discover related content
Find related publications, people, projects and more using interactive charts.

View graph of relations

Related by author

  1. Non-typeable Haemophilus influenzae associated early pregnancy loss: an emerging neonatal and maternal pathogen

    Cevik, M., Moncayo-Nieto, O. L. & Evans, M. J., 23 Sep 2019, In : Infection. First Online, 4 p.

    Research output: Contribution to journalArticle

  2. Organization and training at national level of antimicrobial stewardship and infection control activities in Europe: an ESCMID cross-sectional survey

    Maraolo, A. E., Ong, D. S. Y., Cimen, C., Howard, P., Kofteridis, D. P., Schouten, J., Mutters, N. T., Pulcini, C. & ESGAP-EUCIC-TAE Working Group on AMS/IPC mapping in Europe, 8 Aug 2019, In : European Journal of Clinical Microbiology and Infectious Diseases. First Online, 8 p.

    Research output: Contribution to journalArticle

  3. Social media to engage, communicate and interact

    Cevik, M., 23 Jul 2019, In : Clinical Microbiology and Infection.

    Research output: Contribution to journalEditorial

  4. Management of orbital complications of acute rhinosinusitis in pediatric patients: a 15-Year single-center experience

    Trivić, A., Cevik, M., Folić, M., Krejovic-Trivić, S., Rubino, S., Micić, J., Stevanović, G., Milovanović, J., Jotić, A. & Barać, A., 8 Jul 2019, In : Pediatric Infectious Disease Journal. Online First

    Research output: Contribution to journalArticle

  5. Transfusion-transmitted malaria: a systematic review and meta-analysis

    Ahmadpour, E., Foroutan-Rad, M., Majidiani, H., Moghaddam, S. M., Hatam-Nahavandi, K., Hosseini, S-A., Rahimi, M. T., Barac, A., Rubino, S., Zarean, M., Mathioudakis, A. G. & Cevik, M., Jul 2019, In : Open Forum Infectious Diseases. 6, 7, 8 p., ofz283.

    Research output: Contribution to journalArticle

ID: 258722041